Topicals and CBD-based skincare products are opening new doors for the cannabis industry.

As CBD products begin to enter mainstream retail outlets, they could create a whole generation of consumers whose first experience with cannabinoids will have nothing to do with getting high. Some of the world’s largest brands have been searching for a way to get in on the CBD boom while avoiding complications as the regulatory landscape for cannabis products solidifies. A number of American cannabis companies have discovered the opportunity presented by topical products, offering CBD-infused selections that improve the look, feel and health of the consumer’s skin.


Non-psychoactive CBD is the fastest-growing segment of the cannabis industry. Grand View Research projects that the global CBD market could experience a compound annual growth rate of 32.6 percent to reach US$9.69 billion by 2025. The research firm projects that the global CBD skincare segment of the market may grow at a compound annual growth rate of 32.9 percent to reach US$1.7 billion by 2025.

 

What you need to know about Tesla's Battery Day

   
Expert Analysis of Tesla's Battery Day and the impact on Battery Metals Investing.

Topicals go mainstream

The full extent of CBD’s effectiveness is still a matter of study, but the evidence supporting its remedial effects to date has been enough for CBD to be used in a wide range of skincare applications. CBD binds with CB2 receptors found in immune cells throughout the body and encourages increased production of endocannabinoids, which help reduce inflammation. When used topically, CBD binds specifically with the CB2 receptors in the skin. CBD-based acne treatments leverage CBD’s anti-inflammatory properties to reduce redness and decrease the production of sebum oil that triggers breakouts. Those same properties can also soothe the skin, making CBD useful for reducing sensitive skin and itchiness. CBD is thought to have antioxidant properties, which could help reduce wrinkles and skin dullness.

At US$123.81 billion in 2018, skincare is already an extremely large market, and CBD can be added to the plethora of existing product categories. Just about any product that can be found at a Body Shop outlet can be infused with CBD oils. Lotions, salves, soaps, bath balms, face masks, eye serums and much more are already massively popular products. The introduction of CBD is the latest trend that has the potential to create new growth in the space. Furthermore, the skincare market offers unique opportunities to design products that stand out with unique scents, colors and eye-catching packaging.

CBD skincare topicals are able to clear legal hurdles that other cannabis products cannot. The passing of the US farm bill and hemp farming act in 2018 removed hemp, which contains less than 0.3 percent THC, from the list of schedule one banned substances, enabling the legal production and distribution of hemp-derived CBD products throughout the country. The FDA is still in the process of developing regulations and guidelines for CBD-based medicines and supplements, creating a legal grey area for the sale of such products. CBD skincare topicals, on the other hand, are subject to far less regulatory scrutiny, making these products much less of a liability for retailers. As a result, major retailers like Whole Foods, Walgreens (NASDAQ:WBA), Urban Outfitters (NASDAQ:URBN) and American Eagle Outfitters (NYSE:AEO) are now stocking CBD topicals. Because CBD is not psychoactive, CBD skincare products can be attractively branded and marketed towards consumers of all ages.

“The personal care and beauty industry have been growing rapidly and top-performing segments for millennial and generation Z spend. CBD products that are quality formulations at attractive price points are positioned to win in these growing categories,” said a Green Growth Brands (CSE:GGB,OTCQB:GGBXF) spokesperson.

CBD’s acceptance from mainstream retail outlets has the potential to significantly widen the consumer base for cannabis products. The skincare industry is already very adept at creating targeted products that appeal to the specific health and beauty goals of broad swaths of consumers. CBD provides a useful tool for product formulation, but it also allows the cannabis industry to tap into the massive and diverse skincare consumer base. Huge segments of skincare consumers are people who would not otherwise have tried cannabis products.

Topicals embraced by major retailers

Green Growth Brands is one of the first companies to bring CBD topicals into malls across North America. The company has partnered with retail brands like Abercrombie & Fitch (NYSE:ANF) and American Eagle to offer CBD infused skincare products in their stores. Green Growth has also partnered with Brookfield Properties, which owns 160 shopping centers throughout the United States. Through this partnership, Green Growth plans to open 70 of its own The+Source retail locations in Brookfield malls across the country, leveraging its own extensive experience in the American retail landscape. Members of the company’s leadership have previously helped run major retail brands including Victoria’s Secret, DSW, Bath & Body Works, Calvin Klein and others.

Major consumer goods manufacturers are getting in on the CBD trend as well. L’oreal (EPA:OR) has released CBD-infused products like Kiehl’s Cannabis Serum, and Unilever (LSE:ULVR) is selling Murad’s Hemp Serum. Urban Outfitters has similarly partnered with cannabis company iAnthus Capital Holdings to conduct a trial that will see products from iAnthus’ CBD For Life brand sold in two California and four New York Urban Outfitters locations.

Takeaway

CBD skincare topicals could be the most accessible cannabis products for the mainstream retail landscape, which makes them the least risky proposition for manufacturers and retail outlets. Full regulatory acceptance and mainstream retail adoption might be an ongoing process for some cannabis companies, but CBD topicals are already beginning to hit the mainstream.

This article was written according to INN editorial standards to educate investors.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less